Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

iBio (IBIO) EBIT Margin (2016 - 2025)

iBio (IBIO) has disclosed EBIT Margin for 16 consecutive years, with 5951.0% as the latest value for Q3 2025.

  • On a quarterly basis, EBIT Margin changed N/A to 5951.0% in Q3 2025 year-over-year; TTM through Dec 2025 was 8491.0%, a 434167.0% decrease, with the full-year FY2025 number at 4650.5%, up 274239.0% from a year prior.
  • EBIT Margin was 5951.0% for Q3 2025 at iBio, down from 2599.0% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 377.11% in Q1 2022 to a low of 10206.0% in Q3 2023.
  • A 5-year average of 3603.94% and a median of 2209.5% in 2024 define the central range for EBIT Margin.
  • Biggest YoY gain for EBIT Margin was 323111bps in 2021; the steepest drop was -453146bps in 2021.
  • iBio's EBIT Margin stood at 6220.24% in 2021, then surged by 94bps to 377.11% in 2022, then crashed by -2606bps to 10206.0% in 2023, then surged by 78bps to 2209.5% in 2024, then crashed by -169bps to 5951.0% in 2025.
  • Per Business Quant, the three most recent readings for IBIO's EBIT Margin are 5951.0% (Q3 2025), 2599.0% (Q2 2025), and 2209.5% (Q4 2024).